The University of Chicago Header Logo

Connection

Tao Xie to Humans

Back to Details
This is a "connection" page, showing publications Tao Xie has written about Humans.
Tao Xie
Connection Strength
0.491
Humans
  1. Using Downgaze Palsy Progression Rate to Model Survival in Progressive Supranuclear Palsy-Richardson Syndrome. Mov Disord. 2023 02; 38(2):304-312.
    View in: PubMed
    Score: 0.030
  2. Disparities in diagnosis, treatment and survival between Black and White Parkinson patients. Parkinsonism Relat Disord. 2021 06; 87:7-12.
    View in: PubMed
    Score: 0.026
  3. Disease course and treatment patterns in progressive supranuclear palsy: A real-world study. J Neurol Sci. 2021 Feb 15; 421:117293.
    View in: PubMed
    Score: 0.026
  4. Interference of subcutaneous implantable cardioverter defibrillator by deep brain stimulation. Parkinsonism Relat Disord. 2020 12; 81:75-77.
    View in: PubMed
    Score: 0.025
  5. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J Neurol Neurosurg Psychiatry. 2018 09; 89(9):989-994.
    View in: PubMed
    Score: 0.021
  6. Comments on the recent viewpoint article on low-frequency deep brain stimulation for Parkinson's disease. Mov Disord. 2017 01; 32(1):176.
    View in: PubMed
    Score: 0.019
  7. Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307.
    View in: PubMed
    Score: 0.019
  8. Author Response. Neurology. 2015 Aug 11; 85(6):557.
    View in: PubMed
    Score: 0.018
  9. Respiratory dyskinesia in a patient with Parkinson disease successfully treated with STN DBS. Neurology. 2015 Aug 04; 85(5):479-80.
    View in: PubMed
    Score: 0.018
  10. Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology. 2015 Jan 27; 84(4):415-20.
    View in: PubMed
    Score: 0.017
  11. DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. Neurology. 2014 Feb 18; 82(7):636-7.
    View in: PubMed
    Score: 0.016
  12. Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology. 2012 Oct 16; 79(16):1744; author reply 1744.
    View in: PubMed
    Score: 0.015
  13. Diagnostic biomarkers of Parkinson's disease: what gain at what cost? J Neurol Neurosurg Psychiatry. 2012 Aug; 83(8):769.
    View in: PubMed
    Score: 0.014
  14. Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2012 Oct; 83(10):1015-7.
    View in: PubMed
    Score: 0.014
  15. Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation. Mov Disord. 2012 May; 27(6):799-800.
    View in: PubMed
    Score: 0.014
  16. Using global team science to identify genetic parkinson's disease worldwide. Ann Neurol. 2019 08; 86(2):153-157.
    View in: PubMed
    Score: 0.012
  17. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations. Parkinsonism Relat Disord. 2019 03; 60:138-145.
    View in: PubMed
    Score: 0.011
  18. CSF neurofilament light chain and phosphorylated tau 181 predict disease progression in PSP. Neurology. 2018 01 23; 90(4):e273-e281.
    View in: PubMed
    Score: 0.010
  19. Dystonia treatment: Patterns of medication use in an international cohort. Neurology. 2017 Feb 07; 88(6):543-550.
    View in: PubMed
    Score: 0.010
  20. Progression of brain atrophy in PSP and CBS over 6 months and 1 year. Neurology. 2016 Nov 08; 87(19):2016-2025.
    View in: PubMed
    Score: 0.010
  21. Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol. 2014 Jul; 13(7):676-85.
    View in: PubMed
    Score: 0.008
  22. Common Variants Near ZIC1 and ZIC4 in Autopsy-Confirmed Multiple System Atrophy. Mov Disord. 2022 10; 37(10):2110-2121.
    View in: PubMed
    Score: 0.007
  23. Recommendations for Virtual Administration of the PSP Rating Scale. Mov Disord. 2022 09; 37(9):1960-1961.
    View in: PubMed
    Score: 0.007
  24. A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments. Mov Disord. 2022 06; 37(6):1265-1271.
    View in: PubMed
    Score: 0.007
  25. Pan-cancer analyses reveal genomics and clinical characteristics of the melatonergic regulators in cancer. J Pineal Res. 2021 Oct; 71(3):e12758.
    View in: PubMed
    Score: 0.007
  26. Melatonin reverses nasopharyngeal carcinoma cisplatin chemoresistance by inhibiting the Wnt/ß-catenin signaling pathway. Aging (Albany NY). 2020 03 23; 12(6):5423-5438.
    View in: PubMed
    Score: 0.006
  27. N-Oxide polymer-cupric ion nanogels potentiate disulfiram for cancer therapy. Biomater Sci. 2020 Mar 17; 8(6):1726-1733.
    View in: PubMed
    Score: 0.006
  28. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy. Biomaterials. 2020 05; 240:119902.
    View in: PubMed
    Score: 0.006
  29. Symmetric Arginine Dimethylation Is Selectively Required for mRNA Splicing and the Initiation of Type I and Type III Interferon Signaling. Cell Rep. 2020 02 11; 30(6):1935-1950.e8.
    View in: PubMed
    Score: 0.006
  30. Consensus Paper: Experimental Neurostimulation of the Cerebellum. Cerebellum. 2019 Dec; 18(6):1064-1097.
    View in: PubMed
    Score: 0.006
  31. Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.006
  32. Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Lancet Digit Health. 2019 09; 1(5):e222-e231.
    View in: PubMed
    Score: 0.006
  33. Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Hum Brain Mapp. 2019 12 01; 40(17):5094-5107.
    View in: PubMed
    Score: 0.006
  34. Characterization and implications of estrogenic down-regulation of human catechol-O-methyltransferase gene transcription. Mol Pharmacol. 1999 Jul; 56(1):31-8.
    View in: PubMed
    Score: 0.006
  35. Motor phenotype classification in moderate to advanced PD in BioFIND study. Parkinsonism Relat Disord. 2019 08; 65:178-183.
    View in: PubMed
    Score: 0.006
  36. Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019 06; 18(6):549-558.
    View in: PubMed
    Score: 0.006
  37. Catechol-O-methyltransferase inhibitors in Parkinson's disease. Lancet. 1998 Jun 27; 351(9120):1966.
    View in: PubMed
    Score: 0.005
  38. Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord. 2018 02; 33(2):282-288.
    View in: PubMed
    Score: 0.005
  39. High resolution single strand conformation polymorphism analysis using formamide and ethidium bromide staining. Mol Pathol. 1997 Oct; 50(5):276-8.
    View in: PubMed
    Score: 0.005
  40. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord. 1997 May; 12(3):426-7.
    View in: PubMed
    Score: 0.005
  41. Clinical and demographic characteristics related to onset site and spread of cervical dystonia. Mov Disord. 2016 12; 31(12):1874-1882.
    View in: PubMed
    Score: 0.005
  42. The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort. Mov Disord. 2016 06; 31(6):924-32.
    View in: PubMed
    Score: 0.005
  43. Pathological findings of anti-Yo cerebellar degeneration with Holmes tremor. J Neurol Neurosurg Psychiatry. 2015 Jan; 86(1):121-2.
    View in: PubMed
    Score: 0.004
  44. Anticholinergic responsive cyclic myoclonus. Mov Disord. 2013 Mar; 28(3):401-2.
    View in: PubMed
    Score: 0.004
  45. Distribution of catechol-O-methyltransferase expression in human central nervous system. Neuroreport. 1998 Aug 24; 9(12):2861-4.
    View in: PubMed
    Score: 0.003
  46. Human catechol-O-methyltransferase down-regulation by estradiol. Neuropharmacology. 2003 Dec; 45(7):1011-8.
    View in: PubMed
    Score: 0.002
  47. Further studies in xenobiotic metabolism and Parkinson's disease. Adv Neurol. 2001; 86:105-13.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.